Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Biomedical imaging

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    94 result(s) found for: Biomedical imaging. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2013-005565-40 Sponsor Protocol Number: OTP-B-Linköping Start Date*: 2014-09-11
    Sponsor Name:Department of Biomedical Engineering, Linköping University
    Full Title: Optical measurement with 5-ALA during surgical resection of brain tumors in children
    Medical condition: Tumour border by means of fluorescenstechnique during surgical resection of brain tumours.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003694-15 Sponsor Protocol Number: MK-3475-189 Start Date*: 2016-03-04
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KE...
    Medical condition: non-squamous non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10079440 Non-squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) DE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) BE (Completed) ES (Completed) NL (Completed) FI (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-004869-27 Sponsor Protocol Number: MK-3475-756 Start Date*: 2019-05-03
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Es...
    Medical condition: High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000294-13 Sponsor Protocol Number: MK-3475-086 Start Date*: 2015-06-12
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) - (KEYNOTE-086)
    Medical condition: Triple-Negative Breast Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003644-40 Sponsor Protocol Number: MK-3475-199 Start Date*: 2016-06-06
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-199)
    Medical condition: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) IE (Completed) DE (Completed) SE (Completed) ES (Completed) EE (Completed) NL (Completed) PL (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004567-36 Sponsor Protocol Number: MK-3475-240 Start Date*: 2016-05-13
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)
    Medical condition: Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) DE (Completed) DK (Completed) HU (Completed) FR (Completed) GB (GB - no longer in EU/EEA) PL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004309-15 Sponsor Protocol Number: MK-3475-604 Start Date*: 2017-05-10
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK 3475/SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of...
    Medical condition: First-line treatment of extensive stage small cell lung cancer (ES-SCLC) in combination with standard of care (SOC) chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) PL (Completed) FR (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-001852-32 Sponsor Protocol Number: 3475-164 Start Date*: 2015-12-11
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Treated Locally Advanced Unresectable or Metastatic (Stage IV) Mismatched Repair Deficient or Microsatellite I...
    Medical condition: Colorectal Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-000714-37 Sponsor Protocol Number: MK-3475-799 Start Date*: 2018-11-05
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Canc...
    Medical condition: Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-000972-88 Sponsor Protocol Number: MK3475-062 Start Date*: 2015-08-20
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
    Full Title: A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cispla...
    Medical condition: Gastric or Gastroesophageal Junction Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) DE (Completed) LV (Completed) NL (Completed) ES (Completed) CZ (Completed) FR (Completed) AT (Completed) HU (Completed) BE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004566-28 Sponsor Protocol Number: MK-3475-224 Start Date*: 2016-06-14
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2 Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma (KEYNOTE-224)
    Medical condition: Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002028-41 Sponsor Protocol Number: HPX-2011-003 Start Date*: 2014-01-17
    Sponsor Name:Oxford University Hospitals NHS Trust
    Full Title: A study to determine regional lung function in patients with Non-small cell lung cancer (NSCLC) undegoing radiotherapy using hyperpolarised xenon gas MR imaging
    Medical condition: Non-small cell lung cancer.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-003574-16 Sponsor Protocol Number: MK3475-059 Start Date*: 2015-05-08
    Sponsor Name:Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.
    Full Title: A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil in Subjects with Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcino...
    Medical condition: Gastric Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) LT (Completed) EE (Completed) FR (Completed) RO (Temporarily Halted) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002782-32 Sponsor Protocol Number: MK-3475-181 Start Date*: 2015-12-14
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs. Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma...
    Medical condition: Esophageal Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030155 Oesophageal carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NO (Completed) EE (Completed) PT (Completed) FI (Completed) ES (Completed) DE (Completed) DK (Completed) CZ (Completed) NL (Completed) FR (Completed) IE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001020-27 Sponsor Protocol Number: 3475119 Start Date*: 2015-10-15
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer (mTNBC) – (KEYNOTE-119)
    Medical condition: Metastatic Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) NL (Completed) BE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) PL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004740-11 Sponsor Protocol Number: MK-3475-522 Start Date*: 2017-03-13
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Trip...
    Medical condition: Neoadjuvant and adjuvant treatment for locally-advanced TNBC
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) IE (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) PT (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001139-38 Sponsor Protocol Number: 3475-689 Start Date*: 2018-02-02
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for StageIII-IVA Resectable Locoregionally Ad...
    Medical condition: Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned) ES (Restarted) HU (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) FR (Trial now transitioned) AT (Trial now transitioned) IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002427-26 Sponsor Protocol Number: 3475-180 Start Date*: 2016-02-18
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II Study of Pembrolizumab Monotherapy in Third-Line Previously Treated Subjects with Advanced/Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus or Advanced/Metastatic Si...
    Medical condition: Esophageal Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030155 Oesophageal carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-000229-38 Sponsor Protocol Number: MK-3475-407 Start Date*: 2016-07-15
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cance...
    Medical condition: metastatic squamous NSCLC
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023775 Large cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001245 Adenosquamous cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001247 Adenosquamous cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) NL (Completed) ES (Completed) HU (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-000669-35 Sponsor Protocol Number: MK-3475-716 Start Date*: 2018-10-15
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716)
    Medical condition: High-risk Stage II melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 11:56:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA